Evidence map›Paper›PMID 37279924›Full record

ArticleThe Journal of infectious diseases2023

Bivalent Coronavirus Disease 2019 Vaccine Antibody Responses to Omicron Variants Suggest That Responses to Divergent Variants Would Be Improved With Matched Vaccine Antigens.

Wei Wang, Emilie Goguet, Stephanie Paz, Russell Vassell, Simon Pollett, Edward Mitre, Carol D Weiss

Abstract read
In one paragraph

Article in The Journal of infectious diseases, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Wei WangCenter for Biologics Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland.
Emilie GoguetDepartment of Microbiology and Immunology, Uniformed Services University of the Health Sciences, Bethesda, Maryland.ORCID 0000-0001-6284-4346
Stephanie PazCenter for Biologics Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland.
Russell VassellCenter for Biologics Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland.
Simon PollettHenry M. Jackson Foundation for the Advancement of Military Medicine, Inc, Bethesda, Maryland.
Edward MitreDepartment of Microbiology and Immunology, Uniformed Services University of the Health Sciences, Bethesda, Maryland.ORCID 0000-0001-7506-3266
Carol D WeissCenter for Biologics Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland.ORCID 0000-0002-9965-1289

Funding

DATA CENTER FOR EPIDEMIOLOGIC INVESTIGATIONS OF HIVN01AI005072 · NIAID · NEW ENGLAND RESEARCH INSTITUTES, INC. · PI MCKINLAY, SONJA M · 1990 to 1994
–
NIAID NIH HHS Y01 AI005072
6 · The paper itself

Abstract

We compared neutralizing antibody responses to BA.4/5, BQ.1.1, XBB, and XBB.1.5 Omicron severe acute respiratory syndrome coronavirus 2 variants after a bivalent or ancestral coronavirus disease 2019 (COVID-19) messenger RNA booster vaccine or postvaccination infection. We found that the bivalent booster elicited moderately high antibody titers against BA.4/5 that were approximately 2-fold higher against all Omicron variants than titers elicited by the monovalent booster. The bivalent booster elicited low but similar titers against both XBB and XBB.1.5 variants. These findings inform risk assessments for future COVID-19 vaccine recommendations and suggest that updated COVID-19 vaccines containing matched vaccine antigens to circulating divergent variants may be needed.

Indexed as

Antibody FormationCOVID-19Antibodies, NeutralizingAntibodies, ViralCOVID-19 VaccinesHumansSARS-CoV-2Antibodies, NeutralizingAntibodies, ViralCOVID-19 Vaccinesbivalent COVID-19 vaccineCOVID-19 vaccineOmicronSARS-CoV-2 variants

Identifiers

PMID37279924
PMCPMC10428200

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.